Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07804056 | A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer | recruiting | Phase 3 | 194 | Hamlet Pharma ABINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07830225 | A Pilot Study of ctDNA-Guided Immune Checkpoint Inhibitor Duration in Patients With Advanced Melanoma. | recruiting | N/A | 35 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 21, 2026 |
| clinicaltrials |
| NCT07830407 | Pre-Clinical Validation of ChemoINTEL Unified Algorithm Chemotherapeutic Response Prediction in Patients With Colorectal Cancer | recruiting | — | 100 | Pierian BiosciencesINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831369 | VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma | recruiting | Phase 2 | 52 | Inova Health Care ServicesOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831772 | REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma(REMIND) | recruiting | N/A | 4 | University of MinnesotaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831824 | Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])(SPARROW) | recruiting | Phase 2 / Phase 3 | 408 | Lantheus Medical ImagingINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831902 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer(NSMP-ORANGE) | recruiting | Phase 3 | 600 | University College, LondonOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831993 | Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer | recruiting | Phase 2 | 54 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07832006 | Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 30 | Shunda DuOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT00801489 | Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | recruiting | Phase 2 | 270 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03214562 | Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03630991 | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy | recruiting | Phase 1 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03796559 | Magseed Enabled Long-Term Localization of Axillary Lymph Nodes(MAGELLAN) | recruiting | N/A | 65 | Endomagnetics Ltd.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03943316 | Prospective Laboratory Study Biologic Specimens and Tumor Tissue of Patients With Cancer | recruiting | — | 500 | New Mexico Cancer Research AllianceOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04038619 | Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients | recruiting | Phase 1 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04693468 | Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial | recruiting | Phase 1 | 111 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04752826 | BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) | recruiting | Phase 1 / Phase 2 | 250 | BioInvent International ABINDUSTRY | 7 | Sep 18, 2026 | clinicaltrials |
| NCT05027633 | Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA) | recruiting | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05048212 | A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases | recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05267626 | Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 159 | Aulos Bioscience, Inc.INDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT05327686 | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial(SAMURAI) | recruiting | Phase 2 | 240 | NRG OncologyOTHER | 4 | Sep 18, 2026 | clinicaltrials |
| NCT05615636 | A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL | recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05694650 | Perceptions of Hospital Care at Home for Patients With Cancer: A Qualitative Study of Cancer Providers, Patients and Caregivers. | recruiting | — | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06085729 | Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) | recruiting | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06161545 | Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06191263 | Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML(RIVER-81) | recruiting | Phase 2 | 98 | Ryvu Therapeutics SAINDUSTRY | 4 | Sep 18, 2026 | clinicaltrials |
| NCT06271941 | Reducing Neoplasia Recurrence After Endoscopic Resection of Large Colorectal Polyps(ABLATION) | recruiting | N/A | 892 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06284486 | A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib | recruiting | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06398418 | R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors | recruiting | Phase 1 | 33 | Rise Therapeutics LLCINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06507878 | Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.(GRASSROOT) | recruiting | — | 459 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06512350 | Identifying Patterns in the Breath of Individuals With Breast Cancer | recruiting | — | 5,175 | Breathe BioMedical IncINDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT06534437 | MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)(JASPIS-01) | recruiting | Phase 2 | 178 | Ryvu Therapeutics SAINDUSTRY | 4 | Sep 18, 2026 | clinicaltrials |
| NCT06662409 | Support for Bereaved Cancer Caregivers | recruiting | N/A | 70 | Michigan State UniversityOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06678126 | Adaptive Versus Non-adaptive Radiotherapy and 2 Bladder Filling Instructions for Patients With Intermediate or High Risk Localized Prostate Cancer (ARP) | recruiting | Phase 2 | 104 | Scott TyldesleyOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06692738 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 3 | 1,160 | AstraZenecaINDUSTRY | 26 | Sep 18, 2026 | clinicaltrials |
| NCT06767514 | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1(HARMONi-7) | recruiting | Phase 3 | 780 | Summit TherapeuticsINDUSTRY | 17 | Sep 18, 2026 | clinicaltrials |
| NCT06769490 | Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia | recruiting | Phase 1 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06817720 | Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06900595 | Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer | recruiting | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06948552 | Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA | recruiting | Phase 2 | 10 | Henry Ford Health SystemOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06952803 | A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation(EvoPAR-PR02) | recruiting | Phase 3 | 700 | AstraZenecaINDUSTRY | 28 | Sep 18, 2026 | clinicaltrials |
| NCT06954116 | Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence(CCGLC-017) | recruiting | Phase 2 | 26 | Tongji HospitalOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07089641 | ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial | recruiting | Phase 1 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07210047 | Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients | recruiting | Phase 1 / Phase 2 | 21 | HuniLife Biotechnology, Inc.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07227610 | Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT) | recruiting | Phase 2 | 54 | Medical University of South CarolinaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07298083 | DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins | recruiting | — | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07340541 | Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies(EVOLVE-BDT) | recruiting | Phase 2 | 700 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
Data updated 6 days agoSource updated Sep 21, 2026source: clinicaltrials